Published date: Jul 04 2017

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 12 (2017), Issue No. 2

Pages: 114-118

DOI: 10.18502/sjms.v12i2.921

Kamal Eldein H. Mohamed

Sarah Mirghani

This is a case of 32 years old nulliparous female who was diagnosed  in November 2004 as a case of carcinoma of the right breast , luminal A , (Estrogen Receptor positive Progesterone receptor negative, Her 2 negative, Ki67 10 %), poorly differentiated invasive ductal cancer, TNM stage,T2 N0 MO.  She had a wide local excision and axillary clearance. As she is a case of low risk early stage luminal A breast cancer; she was not given chemotherapy, instead she had a course of external irradiation and was put on Tamoxifen (Astra Zeneca, 20 mg daily), and was advised not to get pregnant during this treatment,but she got pregnant and delivered normally a healthy infant, although Tamoxifen is potentially teratogenic.

[1] A. Elamin, M. E. Ibrahim, D. Abuidris, K. E. H. Mohamed, and S. I. Mohammed, “Part I: Cancer in Sudan-burden, distribution, and trends breast, gynecological, and prostate cancers,” Cancer Medicine, vol. 4, no. 3, pp. 447–456, 2015.

[2] T. T. White, “Carcinoma of the Breast and Pregnancy,” Annals of Surgery, vol. 139, no. 1, pp. 9–18, 1954.

[3] T. Iguchi, M. Hirokawa, and N. Takasugi, “Occurence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen,” Toxicology, vol. 42, no. 1, pp. 1–11, 1986.

[4] K. Tewari, R. G. Bonebrake, T. Asrat, and A. M. Shanberg, “Ambiguous genitalia in infant exposed to tamoxifen in utero,” Lancet, vol. 350, no. 9072, p. 183, 1997.

[5] S. L. Cullins, G. Pridjian, and C. M. Sutherland, “Goldenhar’s Syndrome Associated With Tamoxifen Given to the Mother During Gestation,” JAMA: The Journal of the American Medical Association, vol. 271, no. 24, pp. 1905–1906, 1994.

[6] J. C. Berger and C. L. Clericuzio, “Pierre robin sequence associated with first trimester fetal tamoxifen exposure,” American Journal of Medical Genetics, Part A, vol. 146, no. 16, pp. 2141–2144, 2008.

[7] B. Geert, H. Denys, O. de Wever, V. Cocquyt, and R. van den Broeck, “Use of tamoxifen before and during pregnancy,” Oncologist, vol. 16, no. 11, pp. 1547–1551, 2011.

[8] K. Koizumi and T. Aono, “Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas,” Fertility and Sterility, vol. 46, no. 2, pp. 312–314, 1986.

[9] R. J. Isaacs, W. Hunter, and K. Clark, “Tamoxifen as systemic treatment of advanced breast cancer during pregnancy - Case report and literature review,” Gynecologic Oncology, vol. 80, no. 3, pp. 405–408, 2001.

[10] B. Geert, H. Denys, O. de Wever, V. Cocquyt, and R. van den Broeck, “Use of tamoxifen before and during pregnancy,” Oncologist, vol. 16, no. 11, pp. 1547–1551, 2011.

[11] S. Clark, “Prophylactic tamoxifen,” The Lancet, vol. 342, no. 8864, p. 168, 1993.

[12] E. Koca, T. Y. Kuzan, T. Babacan, I. H. Turkbeyler, F. Sarici, and K. Altundag, “Safety of tamoxifen during pregnancy: 3 case reports and review of the literature,” Breast Care, vol. 8, no. 6, pp. 453–454, 2013.